New drug cocktail aims to tame advanced colon cancer
NCT ID NCT04564898
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a combination of three drugs—trifluridine/tipiracil, capecitabine, and bevacizumab—can safely control metastatic colorectal cancer in people who are not healthy enough for standard intensive chemotherapy. The first part finds the best dose, and the second part checks how well the combo shrinks tumors. About 48 adults with previously untreated metastatic disease are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trifluridine/tipiracil, capecitabine, and bevacizumab
What this could lead to
If successful, this could offer a new, less intensive treatment option for people with metastatic colorectal cancer who cannot tolerate strong chemotherapy.
What could go wrong
This is an early-phase trial with only 48 participants, so the combination may prove too toxic or not effective enough. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero Universitaria Pisana
Pisa, PI, 56126, Italy
-
Fondazione IRCCS Istituto Nazionale Tumori
Milan, MI, 20133, Italy